ACCC logo
Facebook  LinkedIn  Twitter  ACCC Youtube Channel  ACCCBuzz blog

Association of Community Cancer Centers

The leading education and advocacy organization for the multidisciplinary cancer team

ACCCBuzz Blog  Find a Cancer Program  Log in to MyNetwork

Home > Mediaroom > Press Releases > 2008 > Association of Community Cancer Centers to Honor Pioneering Researcher Judah Folkman, MD

FOR INFORMATION CONTACT:
Lori Gardner, Senior Director
Communications & Marketing
301.984.9496 ext. 226
lgardner@accc-cancer.org

ACCC News Release

For Immediate Release: April 1, 2008

Association of Community Cancer Centers to Honor Pioneering Researcher Judah Folkman, MD

ROCKVILLE, Md.—Judah Folkman, MD, will be honored with the Association of Community Cancer Centers' Annual Achievement Award for his pioneering research in tumor angiogenesis and his lifelong commitment to the study and treatment of cancer. Dr. Folkman, who passed away suddenly January 14, 2008, at age 74, was professor of cell biology at Harvard Medical School and director of the Vascular Biology Program at Children’s Hospital and Harvard Medical School. His discovery of how angiogenesis contributes to tumor growth led to clinical testing of numerous drug candidates aimed at preventing the formation of blood vessels that feed cancers.

Dr. Folkman was the author of 389 original peer-reviewed papers and 106 book chapters and monographs. He also held honorary degrees from 15 universities and was the recipient of numerous national and international awards. He had been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the American Philosophical Society and the Institute of Medicine of the National Academy of Sciences.

In 1971 Dr. Folkman published a seminal paper in the New England Journal of Medicine, proposing the hypothesis that all tumor growth is angiogenesis-dependent. This founded the field of angiogenesis research and opened a field of investigation now pursued by scientists in many fields worldwide. Dr. Folkman’s laboratory purified the first angiogenic protein from a tumor, discovered the first angiogenesis inhibitors, and initiated clinical trials of antiangiogenic therapy. Today, angiogenesis inhibitors have received FDA approval in the U.S. for cancer and for the treatment of macular degeneration and are also approved in 27 other countries. Largely because of Dr. Folkman's research, the possibility of antiangiogenic therapy is now on a firm scientific foundation, not only in the treatment of cancer, but of many non-neoplastic diseases as well.

Accepting the award on behalf of Dr. Folkman will be a colleague, Steven J. Fishman, MD. Dr. Fishman is co-director of the multidisciplinary Vascular Anomalies Center at Children’s Hospital Boston, and Stuart and Jane Weitzman Family Chair in Surgery. He has a particular focus on developing an understanding and approach to visceral vascular anomalies. Dr. Fishman is the secretary general of the International Society for the Study of Vascular Anomalies (ISSVA).

About the Association of Community Cancer Centers
The Association of Community Cancer Centers (ACCC) is the leading advocacy and education organization for the multidisciplinary cancer care team. More than 23,000 cancer care professionals from over 2,500 hospitals and practices nationwide are affiliated with ACCC. Providing a national forum for addressing issues that affect community cancer programs, ACCC is recognized as the premier provider of resources for the entire oncology care team. Our members include medical and radiation oncologists, surgeons, cancer program administrators and medical directors, senior hospital executives, practice managers, pharmacists, oncology nurses, radiation therapists, social workers, and cancer program data managers. For more information, visit ACCC's website at www.accc-cancer.org. Follow us on Facebook, Twitter, LinkedIn, and read our blog, ACCCBuzz.

Copyright © 2017 Association of Community Cancer Centers. All Rights Reserved.
1801 Research Boulevard, Suite 400, Rockville, MD 20850  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US